BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31443113)

  • 1. 68Ga-RM2 PET in PSMA- positive and -negative prostate cancer patients.
    Hoberück S; Michler E; Wunderlich G; Löck S; Hölscher T; Froehner M; Braune A; Ivan P; Seppelt D; Zöphel K; Kotzerke J
    Nuklearmedizin; 2019 Sep; 58(5):352-362. PubMed ID: 31443113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.
    Minamimoto R; Hancock S; Schneider B; Chin FT; Jamali M; Loening A; Vasanawala S; Gambhir SS; Iagaru A
    J Nucl Med; 2016 Apr; 57(4):557-62. PubMed ID: 26659347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
    Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
    Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.
    Kabasakal L; Demirci E; Ocak M; Akyel R; Nematyazar J; Aygun A; Halac M; Talat Z; Araman A
    Nucl Med Commun; 2015 Jun; 36(6):582-7. PubMed ID: 25738559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist
    Wieser G; Popp I; Christian Rischke H; Drendel V; Grosu AL; Bartholomä M; Weber WA; Mansi R; Wetterauer U; Schultze-Seemann W; Meyer PT; Jilg CA
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1463-1472. PubMed ID: 28417160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of
    Schollhammer R; Robert G; Asselineau J; Yacoub M; Vimont D; Balamoutoff N; Bladou F; Bénard A; Hindié E; Gallerande HC; Morgat C
    J Nucl Med; 2023 Mar; 64(3):379-385. PubMed ID: 36215569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
    Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
    Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
    Aggarwal R; Wei X; Kim W; Small EJ; Ryan CJ; Carroll P; Cooperberg M; Evans MJ; Hope T
    Eur Urol Oncol; 2018 May; 1(1):78-82. PubMed ID: 31100231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Bone Uptake in Bone Scan and Ga-68 PSMA PET/CT Images in Patients with Prostate Cancer.
    Acar E; Bekiş R; Polack B
    Curr Med Imaging Rev; 2019; 15(6):589-594. PubMed ID: 32008568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.
    Dewes S; Schiller K; Sauter K; Eiber M; Maurer T; Schwaiger M; Gschwend JE; Combs SE; Habl G
    Radiat Oncol; 2016 May; 11():73. PubMed ID: 27229485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET.
    Farolfi A; Ilhan H; Gafita A; Calais J; Barbato F; Weber M; Afshar-Oromieh A; Spohn F; Wetter A; Rischpler C; Hadaschik B; Pianori D; Fanti S; Haberkorn U; Eiber M; Herrmann K; Fendler WP
    J Nucl Med; 2020 Jul; 61(7):1037-1042. PubMed ID: 31806773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated
    Lütje S; Cohnen J; Gomez B; Grüneisen J; Sawicki L; Rübben H; Bockisch A; Umutlu L; Pöppel TD; Wetter A
    Nuklearmedizin; 2017 Jun; 56(3):73-81. PubMed ID: 28401244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced Acquisition Time per Bed Position for PET/MRI Using
    Duan H; Baratto L; Hatami N; Liang T; Levin CS; Khalighi MM; Iagaru A
    AJR Am J Roentgenol; 2022 Feb; 218(2):333-340. PubMed ID: 34406051
    [No Abstract]   [Full Text] [Related]  

  • 15. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
    J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, Predictive Factors, and Prediction Nomograms for
    Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Duan H; Moradi F; Davidzon GA; Liang T; Song H; Loening AM; Vasanawala S; Srinivas S; Brooks JD; Hancock S; Iagaru A
    Lancet Oncol; 2024 Apr; 25(4):501-508. PubMed ID: 38423030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging GRPr Expression in Metastatic Castration-Resistant Prostate Cancer with [
    Fernández R; Soza-Ried C; Iagaru A; Stephens A; Müller A; Schieferstein H; Sandoval C; Amaral H; Kramer V
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
    Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
    J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.